Literature DB >> 16651409

Reversible kinetic analysis of Myc targets in vivo provides novel insights into Myc-mediated tumorigenesis.

Elizabeth R Lawlor1, Laura Soucek, Lamorna Brown-Swigart, Ksenya Shchors, C Uli Bialucha, Gerard I Evan.   

Abstract

Deregulated expression of the Myc transcription factor is a frequent causal mutation in human cancer. Thousands of putative Myc target genes have been identified in in vitro studies, indicating that Myc exerts highly pleiotropic effects within cells and tissues. However, the complexity and diversity of Myc gene targets has confounded attempts at identifying which of these genes are the critical targets mediating Myc-driven tumorigenesis in vivo. Acute activation of Myc in a reversibly switchable transgenic model of Myc-mediated beta cell tumorigenesis induces rapid tumor onset, whereas subsequent Myc deactivation triggers equally rapid tumor regression. Thus, sustained Myc activity is required for tumor maintenance. We have used this reversibly switchable kinetic tumor model in combination with high-density oligonucleotide microarrays to develop an unbiased strategy for identifying candidate Myc-regulated genes responsible for maintenance of Myc-dependent tumors. Consistent with known Myc functions, some Myc-regulated genes are involved in cell growth, cycle, and proliferation. In addition, however, many Myc-regulated genes are specific to beta cells, indicating that a significant component of Myc action is cell type specific. Finally, we identify a very restricted cadre of genes with expression that is inversely regulated upon Myc activation-induced tumor progression and deactivation-induced tumor regression. By definition, such genes are candidates for tumor maintenance functions. Combining reversibly switchable, transgenic models of tumor formation and regression with genomic profiling offers a novel strategy with which to deconvolute the complexities of oncogenic signaling pathways in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16651409     DOI: 10.1158/0008-5472.CAN-05-3826

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

Review 1.  Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.

Authors:  Louis Chesler; William A Weiss
Journal:  Semin Cancer Biol       Date:  2011-09-21       Impact factor: 15.707

Review 2.  MYC: connecting selective transcriptional control to global RNA production.

Authors:  Theresia R Kress; Arianna Sabò; Bruno Amati
Journal:  Nat Rev Cancer       Date:  2015-09-18       Impact factor: 60.716

Review 3.  Control of vertebrate development by MYC.

Authors:  Peter J Hurlin
Journal:  Cold Spring Harb Perspect Med       Date:  2013-09-01       Impact factor: 6.915

4.  Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance.

Authors:  Catherine M Shachaf; Andrew J Gentles; Sailaja Elchuri; Debashis Sahoo; Yoav Soen; Orr Sharpe; Omar D Perez; Maria Chang; Dennis Mitchel; William H Robinson; David Dill; Garry P Nolan; Sylvia K Plevritis; Dean W Felsher
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

5.  Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites.

Authors:  Javier A Menendez; Tomás Alarcón; Jorge Joven
Journal:  Cell Cycle       Date:  2014-02-03       Impact factor: 4.534

Review 6.  p53--a Jack of all trades but master of none.

Authors:  Melissa R Junttila; Gerard I Evan
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

Review 7.  The ups and downs of Myc biology.

Authors:  Laura Soucek; Gerard I Evan
Journal:  Curr Opin Genet Dev       Date:  2009-12-03       Impact factor: 5.578

8.  c-Myc activates multiple metabolic networks to generate substrates for cell-cycle entry.

Authors:  F Morrish; N Isern; M Sadilek; M Jeffrey; D M Hockenbery
Journal:  Oncogene       Date:  2009-05-18       Impact factor: 9.867

9.  Absence of caspase-3 protects pancreatic {beta}-cells from c-Myc-induced apoptosis without leading to tumor formation.

Authors:  Anna Radziszewska; Stephanie A Schroer; Diana Choi; Panteha Tajmir; Nikolina Radulovich; James C Ho; Linyuan Wang; Nicole Liadis; Razqallah Hakem; Ming-Sound Tsao; Linda Z Penn; Gerard I Evan; Minna Woo
Journal:  J Biol Chem       Date:  2009-02-12       Impact factor: 5.157

10.  Can systems biology understand pathway activation? Gene expression signatures as surrogate markers for understanding the complexity of pathway activation.

Authors:  Hiraku Itadani; Shinji Mizuarai; Hidehito Kotani
Journal:  Curr Genomics       Date:  2008       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.